{"name":"Lykos Therapeutics","slug":"lykos","ticker":"","exchange":"Private","domain":"lykostherapeutics.com","description":"Resilient Pharmaceuticals, formerly known as Lykos Therapeutics and before that as the MAPS Public Benefit Corporation, is a public benefit corporation (PBC) developing MDMA (\"ecstasy\") for potential medicinal use. It was founded and is considerably owned by the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS PBC was founded in 2014 and was renamed to Lykos Therapeutics in January 2024. Subsequently, the company was renamed again to Resilient Pharmaceuticals in August 2025.","hq":"San Jose, CA","founded":0,"employees":"","ceo":"Amy Emerson","sector":"Psychiatry / Psychedelic Medicine","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"Private","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNbEV1R2toOHdnWUk2ZHFRV2V2ekREd1dzS1VqVU5nb0dmb3NRWWhfOXpqQkNpbVoyV2Rodk1XZ2ZlTHJtYVlUWTN6QmZreno1NGdZQmRSZnZucUlQUHBrdVdVelZURUl6MFlrTHluSWNzdmJOSlROYjNjSUFhTmhjZTE5X0dFZmoxeXlHd19EX1laYm1i?oc=5","date":"2026-01-02","type":"pipeline","source":"Psychedelic Alpha","summary":"2025 Year in Review: 10 Standout Stories in Psychedelics - Psychedelic Alpha","headline":"2025 Year in Review: 10 Standout Stories in Psychedelics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOTFVtZmpqdzI4U3VnMzVFd3ctbWFVZ2hNUG82RW54YVlsYnZYcHJULUppVGNfZ3REQ091R3VlRDg3QnYtZWRtZTREMTRhRmczdzRKcXg4V05xZGNfZGEta2czLTBWQWEtRVNsY19YdU9yNlJ5X1ZleW9jLW14dEhiLXVTektRM25jckhpbVQtRkc4Ynli?oc=5","date":"2025-10-30","type":"regulatory","source":"statnews.com","summary":"FDA criticism of MDMA-assisted therapy is an opportunity for psychedelic medicine - statnews.com","headline":"FDA criticism of MDMA-assisted therapy is an opportunity for psychedelic medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOQlJ5S1hGb2NXTzd3akNQYlZEYy13WEdNUGV0NElwTENTOUtYV0Vub1ZKLVlmSkREa0pkcWg5YkdkTENMbkFQTk9wSXhxQzZzVEswV3Bxdzh1ZERkU0g1cTBIQk9zb2pvbmlTUmZsd0JTRzE2OVBOdUpDTXprNllQOHZKa1FIdnJPLWVDdHZkUkI3VXZRR3dXd2Fn?oc=5","date":"2025-09-22","type":"pipeline","source":"BioSpace","summary":"Psychedelics Space Enters New Era as AbbVie Dives In - BioSpace","headline":"Psychedelics Space Enters New Era as AbbVie Dives In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQUzE0cW12bFRZaVhVYWJnTzd3R2N0dGh5dWZfY2xoaUZSdElsN3I3TnNwSWJhNENsc1gyZVRSdnZLYUpla0FQYjhDd1RWaHhobFFQRldtTnhveGlYY0g0SVg3QkxCM09RaW1PWUQtdGxJM0xIbFBCeUFYT2ZDOWx0TURDbEJ6YVVPQ1owdzVfdHZSUlR4SmFZ?oc=5","date":"2025-09-09","type":"pipeline","source":"Politico","summary":"Lykos’ rejection letter - Politico","headline":"Lykos’ rejection letter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE91cnpUcXp1am5CbkNlOEJYWUVQb1U0NEFRNHItVUtnMlZQYWotMmRUOGZMZnEyaGdWeFJQbVRtT19MM0twMHBZeVNEc2lnWl9YTHNiTkpuVXJLcWs?oc=5","date":"2025-09-08","type":"regulatory","source":"Labiotech.eu","summary":"With Lykos CRL now public, FDA opens new era of accountability - Labiotech.eu","headline":"With Lykos CRL now public, FDA opens new era of accountability","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQYTVlN0d6NzB1M1g5N2hlUks0Yk16RGRUd21TZTkyVjBoc095Z0pZV09zaE1QNDRuZTEtZkoxWjhrTW9PdUNNU28wSV9yam1mTjljTTlDV1lxX0RRN1ZXckFyYkQzSl9BNEVBVGl1R1h2Ymg4THloZU9mQnE0RjdlMG0zQ196T2IwREVQeUtRZmhDYUZiUjZMTlU1T0kxc3ZjZVllb202YkZvY29Od3ZBSUVNQlA3UTNHZ0JaVXR6dmEydw?oc=5","date":"2025-09-05","type":"pipeline","source":"BioSpace","summary":"With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’ - BioSpace","headline":"With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOZHRsazkyS0JNOFlrbU1kTHBZYkxkZlR6Y05vMlFwRGZYVHdFR1RoM1ppc0dRd0ZaWFZ5YmU5Vi03Mi03cE5aWHlPc1R0aDNmUmZJZXFyQ3pmWmszUkpremFMNWljNTdmQVZWLWlhbU5JM3hfT3ZJOWstUVFjamlBWTIxZUdYUUd4WFNQNWttNVlJcXVCbGhNRmNFaC1KR05NQXZlQXNWMmZ5SzBTVUR0VTJIUzBiOVMxNWZF?oc=5","date":"2025-09-05","type":"regulatory","source":"Psychiatric Times","summary":"FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD - Psychiatric Times","headline":"FDA Releases Complete Response Letter on Declining MDMA-Assisted Therapy for PTSD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNSnluVHU4Znp2MXRyZ2dXUDFUcXh4VTB2aXNsdzZsVHYwN2poQXZmVHc2TjNtT2xVYWRRQnZJTDlXMXFqV0FuR1NCbUVHUzE3NFFXenBVOS1abklsTDFfLWpITUhFT1FsUnoxN0toazNBYjZ3ano3V2ZJbFU3Z1JXS3VQNmtidkNZWjRBM3dLeGtKcTZEYWdzdDEyQmk5SURBR0pOcDB1bDc?oc=5","date":"2025-09-05","type":"regulatory","source":"Fierce Biotech","summary":"'Several concerning observations': FDA sheds more light on reasons it rejected drugs - Fierce Biotech","headline":"'Several concerning observations': FDA sheds more light on reasons it rejected drugs","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTFBEWDNVRkM4YVV4T0dGRDJKeFpaZE40SmxYbm9RcXpwZGxSdzdteEoxLU9TZ3ozcGNiRzZNVEozR2w3bURTTEtnczRtbWF5OUx4N01wdWFwNmNXLW9xUmhQbDlR?oc=5","date":"2025-08-30","type":"pipeline","source":"futurism.com","summary":"Top Elon Musk Acolyte Running Large MDMA Empire - futurism.com","headline":"Top Elon Musk Acolyte Running Large MDMA Empire","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPVFdYV0lEV2llTDdIY3Qzdk1uRFVPZUtvbFItVFItVUdnaHhuNlFoNExJbnRMeXN1MS1UamNJbENNQ0dDbndWR3hvQ2FINHdTVTBHNTJodXEwZGw1Szg1aWJIalVkTW9oaktwUi1rUmozenVSV2lOM1FXMjhxdGZGY1NrZXM4YU5QWWN4UUJ2R1htVWxWbGROOVRhU3hQcndYUE1HYzNEZzNKN2ZsRXdr?oc=5","date":"2025-05-28","type":"trial","source":"Clinical Trials Arena","summary":"Psychedelic drug developers redesign trials to avoid Lykos faux pas - Clinical Trials Arena","headline":"Psychedelic drug developers redesign trials to avoid Lykos faux pas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxORy10UW80Mi1wNl9GbjJKVHQ3dUpfZ2R6TDMxaWJqQ0hzMjdBUjNuUDRKelNuQUtqQTVjczZWU0E2eDVaa1J3eHI4MFNoMWhUd04xZF9NLVRTMVRaM1JVOFJKNWxzT1F6bGZkbkdnZU1IR0VCeUVLM2xCMWFWSFFnaG16c1JrQVc0Nkt5c1lRSnNJcjhmbDljZ0dsMWRsSUpnZnc?oc=5","date":"2025-04-18","type":"pipeline","source":"Pharma Voice","summary":"A big moment is coming for psychedelics - Pharma Voice","headline":"A big moment is coming for psychedelics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOcVJnYjQtbjRmOVd6S3hvUGNzWmhOUVBuVXJaQVFDYno1Q1ZfWEZCbVQwR3RIUzkyTV9zN3FNSmt4YUR5MWcxTktDSVVablEtSnBHUGE0djJuamM5dFBIUndoYmg4T1RCMUxReVFzQVFNcmwzaXhxeVN4WlItMkZJNm9PUW8tTnF3QnZHWVJUajdtUTBFTk4ydEQtVUJaeGQxcWJoTDZIbFNaUzd2LUpIQ1dB?oc=5","date":"2024-09-16","type":"pipeline","source":"Pharmaceutical Technology","summary":"After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology","headline":"After the Lykos debacle, what’s next for psychedelic therapies?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}